Table 1 Clinical features of metastatic colorectal cancer patients treated with irinotecan-based therapy
Characteristics | Patients (N = 67) |
|---|---|
Median age-years (range) | 62 (33–79) |
Sex | |
Male | 47 (70%) |
Female | 20 (30%) |
Median CEA (range, ng/mL) | 16 (0–2066) |
Performance status WHO | |
0 | 29 (43%) |
1 | 35 (52%) |
2 | 3 (5%) |
Site of primary tumor | |
Colon | 35 (52%) |
Rectum | 32 (48%) |
METASTASIS | |
Liver | 31 (47%) |
Liver & other | 19 (28%) |
Other | 15 (22%) |
N.A. | 2 (3%) |
KRAS | |
Wild-type | 35 (52%) |
Mutated | 26 (39%) |
N.A. | 6 (9%) |
BRAF | |
Wild-type | 60 (90%) |
Mutated | 7 (10%) |
Biologic treatment | |
Bevacizumab | 23 (34%) |
Cetuximab | 7 (11%) |
None | 37 (55%) |
TOPO I expression level | |
High | 21 (31%) |
Low | 20 (30%) |
N.A. | 26 (39%) |
DEK expression level | |
High | 21 (31%) |
Low | 46 (69%) |